Europe Cell Isolation Market (2026-2031)
The Europe Cell Isolation Market was valued at $544.8 Million in 2026 and projected to reach to $917.4 Million by 2031, representing a compound annual growth rate of 11.0%. Europe's cell isolation market is poised for sustained growth through 2031, supported by well-established healthcare infrastructure, significant government funding for life sciences research, and increasing adoption of personalized medicine approaches.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe Cell Isolation Market Trends and Insights
- This 11.0% compound annual growth rate reflects Europe's strong investment in advanced healthcare technologies and regenerative medicine research.
- Europe's mature healthcare infrastructure, coupled with increasing adoption of cell-based therapies and diagnostic applications, positions the region as a key driver of global cell isolation innovation. The European market benefits from stringent regulatory frameworks that ensure product quality and safety, attracting both established pharmaceutical companies and emerging biotech firms.
- Between 2026 and 2031, Europe is expected to see accelerated demand for automated cell isolation systems across clinical laboratories, research institutions, and biopharmaceutical manufacturers.
- Europe's commitment to precision medicine and personalized healthcare further supports sustained market expansion during the forecast period..
Key Market Statistics
- CAGR (2026-2031) 11.0% CAGR
- Market Size, 2026 ~USD 544.8 Million
- Forecast, 2031 ~USD 917.4 Million
- Geography Europe
Europe Cell Isolation Market Overview
Strong Market Valuation :
Europe's cell isolation market is valued at $544.8 million in 2026, with significant growth trajectory driven by advanced healthcare infrastructure and substantial R&D investments across the region.
Robust CAGR Performance :
The European market is expanding at an 11.0% CAGR through 2031, reflecting strong demand for cell-based therapies and diagnostic applications in mature healthcare systems.
Regenerative Medicine Leadership :
Europe leads in regenerative medicine adoption, with countries like Germany and the UK spearheading clinical applications and regulatory frameworks for cell isolation technologies.
Forecast Growth to $917.4M :
By 2031, the European market is projected to reach $917.4 million, representing a 68.5% increase from 2026 levels, driven by expanding therapeutic applications and healthcare modernization.
Europe Cell Isolation Market Dynamics
- The region's regulatory frameworks, particularly in Germany, UK, and France, are facilitating faster commercialization of cell-based therapies and diagnostic solutions. Key growth drivers include rising prevalence of chronic diseases, expanding clinical trial pipelines, and growing investment in stem cell research and regenerative medicine.
- European healthcare providers are increasingly integrating cell isolation technologies into routine diagnostic and therapeutic protocols, positioning the region as a critical market for innovation and clinical implementation of advanced cellular therapies..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Europe's cell isolation market will grow from $544.8M (2026) to $917.4M (2031) at an 11.0% CAGR.
- Europe's regulatory environment and healthcare infrastructure drive adoption of advanced cell isolation technologies.
- Regenerative medicine and cell-based therapies are primary growth catalysts across Europe.
- Europe's precision medicine initiatives support sustained demand for cell isolation systems through 2031.
Cell Isolation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SURFACE MARKER-BASED CELL ISOLATION (Technique) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 12.7% from 2026 to 2031 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 4.38 (2026) |
| Revenue Forecast (Billions) | ~USD 7.97 (2031) |
| Segments Covered | Product, Type, Cell Type, Cell Source, Technique |
Europe Cell Isolation Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product
- Consumables
- Instruments
By Type
- Beads
- Differentiated Cells
- Disposables
- Media & Sera
- Reagents & Kits
- Stem Cells
By Cell Type
- Animal Cells
- Human Cells
By Cell Source
- Adipose Tissue
- Blood & Blood-Derived Samples
- Bone Marrow
- Cord Blood/ Embryonic Stem Cells
- Other Cell Sources
By Technique
- Centrifugation-Based Cell Isolation
- Filtration-Based Cell Isolation
- Microfluidics & Label-Free Cell Isolation
- Surface Marker-Based Cell Isolation
EUROPE: CELL ISOLATION MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 367.5 | 381 | 401.1 | 431.7 | 476.2 | 537.8 | 621.5 | 734.6 | 12.9 |
| HOSPITALS & DIAGNOSTIC LABORATORIES | 160.6 | 165.4 | 172.9 | 184.9 | 202.6 | 227.3 | 261 | 306.5 | 12.1 |
| OTHER END USERS | 115.9 | 118.6 | 123.3 | 131 | 142.8 | 159.3 | 181.8 | 212.3 | 11.5 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 516.4 | 526.4 | 544.8 | 576.5 | 625.4 | 694.6 | 789.3 | 917.4 | 11 |
| TOTAL | 1160.3 | 1191.4 | 1242.2 | 1324.1 | 1447 | 1619 | 1853.7 | 2170.8 | 11.8 |
REST OF EUROPE: CELL ISOLATION MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 83.9 | 85.5 | 88.5 | 93.6 | 101.5 | 112.5 | 127.7 | 148.1 | 10.8 |
| HOSPITALS & DIAGNOSTIC LABORATORIES | 36.8 | 37.2 | 38.3 | 40.2 | 43.3 | 47.7 | 53.8 | 62 | 10.1 |
| OTHER END USERS | 25.9 | 26 | 26.6 | 27.8 | 29.7 | 32.6 | 36.5 | 41.8 | 9.5 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 117.8 | 118.1 | 120.2 | 125 | 133.2 | 145.3 | 162.1 | 184.9 | 9 |
| TOTAL | 264.3 | 266.9 | 273.5 | 286.5 | 307.6 | 338 | 380 | 436.8 | 9.8 |
Target Audience
- Medical Device Manufacturers : Require detailed European market data to develop region-specific product portfolios, navigate regulatory requirements, and identify high-growth country markets for cell isolation equipment.
- Pharmaceutical & Biotech Companies : Need market intelligence on cell-based therapy adoption, clinical trial landscapes, and reimbursement frameworks across European countries to guide R&D and commercialization strategies.
- Healthcare Providers & Hospitals : Seek market insights to evaluate cell isolation technology investments, benchmark adoption rates against peer institutions, and plan integration of advanced diagnostic capabilities.
- Research Institutions & Universities : Require comprehensive market data to secure funding, justify equipment investments, and align research initiatives with commercial opportunities in Europe's growing cell isolation sector.
- Investment & Consulting Firms : Need detailed European market analysis for due diligence, portfolio company benchmarking, and identifying acquisition targets or investment opportunities in the cell isolation space.
Key Companies in the Europe Cell Isolation Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | GeneXpert instruments and Xpert test cartridges,SmartCycler system and reagents,Custom and collaborative programs (USPS BDS, TB, Ebola, new molecular tests), |
| MAXCYTE, INC | United States | Public Company | ExPERT STx and GTx flow electroporation instruments,ExPERT ATx and VLx instruments,Disposable processing assemblies (PAs), |
| GENERAL ELECTRIC | United States | Public Company | Commercial Engines & Services,Defense & Propulsion Technologies, |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use),Life Sciences tools and genomics,Diagnostics, |
| MERCK KGAA | Germany | Public Company | Life Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (oncology, neurology, fertility, rare diseases, cardiovascular, metabolic),Electronics (semiconductor and display materials, specialty gases, delivery equipment), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (syringes, needles, catheters, sharps, vascular care),Connected Care (infusion, dispensing, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, pharma solutions), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| SARTORIUS AG | Germany | Public Company | Bioprocess solutions (bioreactors, cell culture, fluid management, process filtration),Analytical instruments and process analytics,Lab products and services (filtration, water systems, weighing, pipettes, microbiological testing), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research and Bioprocess, |
| QIAGEN | Netherlands | Public Company | Sample technologies (nucleic acid purification & stabilization),Molecular diagnostics assays (immune response, oncology, SRH, viral load),PCR & dPCR instruments and reagents, |
| REVVITY | United States | Public Company | Diagnostics instruments and automation platforms,Diagnostics reagents, assays, and kits,Life science research tools and genomic workflow solutions, |
| CORNING INCORPORATED | United States | Public Company | Optical Communications (fiber, cable, hardware, components),Display Glass Substrates (LCD, OLED),Specialty Materials (mobile, semiconductor optics, defense, radiation shielding, sunglasses), |
| LONZA | Switzerland | Public Company | Integrated Biologics (mammalian and drug product platforms),Advanced Synthesis (small molecules, HPAPIs, ADCs and bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA), |
| BIO-TECHNE | United States | Public Company | Protein Sciences (reagents and proteomic tools),Diagnostics (controls, calibrators, assays, process controls),Spatial Biology and Genomics, |
| TERUMO CORPORATION | Japan | Public Company | Cardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company, |
CEPHEID INC.
Cepheid Inc. is a United States-based private company founded in 1996 with 1,700 employees. The company develops molecular diagnostics and point-of-care testing solutions.
MAXCYTE, INC
MaxCyte, Inc. is a publicly traded United States company founded in 1998 with 91 employees. The company develops cell engineering technologies and platforms.
GENERAL ELECTRIC
General Electric is a publicly traded United States conglomerate founded in 1892 with 57,000 employees. The company operates across multiple industrial and technology sectors.
GE HEALTHCARE
GE Healthcare is a publicly traded United States company established in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
DANAHER CORPORATION
Danaher Corporation is a publicly traded United States company founded in 1969 with 59,000 employees. The company operates a diversified portfolio of businesses in life sciences, diagnostics, and environmental solutions.
MERCK KGAA
Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. The company operates in pharmaceuticals, life sciences, and performance materials.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a publicly traded United States company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a publicly traded United States company founded in 1897 with 72,000 employees. The company manufactures medical devices, laboratory equipment, and diagnostic products.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a publicly traded United States company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
SARTORIUS AG
Sartorius AG is a publicly traded German company founded in 1870 with 14,242 employees. The company manufactures laboratory and bioprocess equipment for pharmaceutical and biotechnology industries.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a publicly traded United States company founded in 1952 with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.
QIAGEN
QIAGEN is a publicly traded Netherlands-based company founded in 1984 with 5,500 employees. The company provides molecular diagnostics, sample preparation, and bioinformatics solutions.
REVVITY
Revvity is a publicly traded United States company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences research and diagnostics.
CORNING INCORPORATED
Corning Incorporated is a publicly traded United States company founded in 1851 with 67,200 employees. The company manufactures specialty glass, ceramics, and laboratory products.
LONZA
Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. The company provides contract manufacturing and life science solutions for pharmaceuticals and biotechnology.
BIO-TECHNE
Bio-Techne is a publicly traded United States company founded in 1976 with 3,100 employees. The company develops and manufactures proteins, antibodies, and reagents for life sciences research.
TERUMO CORPORATION
Terumo Corporation is a publicly traded Japanese company founded in 1921 with 30,591 employees. The company manufactures medical devices and blood management solutions.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 644.7 Million |
| UK | USD 396.4 Million |
| France | USD 150.9 Million |
| Italy | USD 79.8 Million |
| Spain | USD 61.9 Million |
| Rest Of Europe | USD 184.9 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Segmentation : Gain detailed insights into Europe's cell isolation market with country-level breakdowns for Germany, UK, France, Italy, Spain, and Rest of Europe, enabling targeted market entry strategies.
- Growth Trajectory Analysis : Understand the 11% CAGR dynamics and $372.6 million growth opportunity from 2026-2031, with forecasts supporting strategic investment and product development decisions.
- Competitive Landscape Intelligence : Identify market leaders and emerging players across European markets, with insights into regulatory environments, reimbursement policies, and clinical adoption rates by country.
- Technology & Application Trends : Access comprehensive analysis of cell isolation methodologies, therapeutic applications, and diagnostic uses driving adoption across European healthcare systems and research institutions.
- Strategic Market Positioning : Leverage Europe-specific data to benchmark performance, identify white-space opportunities, and develop localized go-to-market strategies for cell isolation solutions and services.
Frequently asked questions
What is the current size of Europe's cell isolation market?
Europe's cell isolation market was valued at $544.8 million in 2026 and is projected to reach $917.4 million by 2031.
What is the expected growth rate for Europe's cell isolation market?
Europe's cell isolation market is expected to grow at an 11.0% compound annual growth rate (CAGR) from 2026 to 2031.
What factors are driving growth in Europe's cell isolation market?
Key drivers include increasing adoption of cell-based therapies, regenerative medicine research, stringent regulatory standards, and Europe's commitment to precision medicine.
Which sectors in Europe are adopting cell isolation technologies?
Europe's clinical laboratories, research institutions, biopharmaceutical manufacturers, and academic medical centers are primary adopters of cell isolation systems.
How does Europe's market compare to global cell isolation market trends?
Europe's 11.0% CAGR is slightly below the global 12.7% CAGR, reflecting Europe's mature market status and established healthcare infrastructure.
RESEARCH METHODOLOGY
This research study extensively used secondary sources, directories, and databases to identify and collect information for analysis of the global cell isolation market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with primary research inputs to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the cell isolation market. The secondary sources used for this study include World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Stem Cell Society Singapore (SCSS), International Society for Advancement of Cytometry (ISAC), American Filtration and Separations Society (AFS), Food and Drug Administration (FDA), American Society for Cell Biology (ASC8), National Institutes of Health (NIH), International Society for Cell & Gene Therapy (ISCT), American Society for Gene and Cell Therapy (ASGCT), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan Agency for Medical Research and Development, European Federation of Pharmaceutical Industries and Associations (EFPIA), and the Alliance for Regenerative Medicine (ARM). Secondary data were collected and analyzed to determine the overall size of the global cell isolation market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the cell isolation market. These methods were also used extensively to estimate the size of various market segments.
Cell Isolation Market/Cell Separation Market : Top-Down and Bottom-Up Approach
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Cell isolation is the process of separating specific cells from a given sample. It is a tool in biological research that enables the isolation of a single cell type from heterogeneous cell populations without contamination by other cell types. This process is widely used for the isolation of biomolecules to produce vaccines, drugs, antibodies, enzymes, proteins, and other biotechnology products.
Key Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Life science companies
- Academic & research institutes
- Private research institutes
- Venture capitalists & investors
- Hospitals and diagnostic laboratories
- Market research & consulting firms
- Medical institutions & universities
Report Objectives
- To define, describe, and forecast the cell isolation market based on product, cell type, cell source, technique, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall cell isolation market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the cell isolation market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the cell isolation market
- To benchmark players within the cell isolation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy
Customization Options :
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
- Further breakdown of the Rest of Europe Cell Isolation Market, by country
- Further breakdown of the Rest of Asia Pacific Cell Isolation Market, by country
- Further breakdown of the Rest of Latin America Cell Isolation Market, by country
- Further breakdown of the Rest of Middle East Cell Isolation Market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Get the Full Cell Isolation Market Report
Full forecast, segment splits, and company analysis for all Cell Isolation Market.
- US Cell Isolation Market
- Canada Cell Isolation Market
- Germany Cell Isolation Market
- UK Cell Isolation Market
- France Cell Isolation Market
- Italy Cell Isolation Market
- Spain Cell Isolation Market
- China Cell Isolation Market
- Japan Cell Isolation Market
- India Cell Isolation Market
- Australia Cell Isolation Market
- South Korea Cell Isolation Market
- Brazil Cell Isolation Market
- Mexico Cell Isolation Market
- Saudi Arabia Cell Isolation Market
- UAE Cell Isolation Market
- Rest Of Europe Cell Isolation Market
- Rest Of Asia Pacific Cell Isolation Market
- Rest Of Latin America Cell Isolation Market
- Rest Of GCC Countries Cell Isolation Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report